Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort.

BACKGROUND: Understanding the global impact of medulloblastoma on health related quality of life (HRQL) is critical to characterizing the broad impact of this disease and realizing the benefits of modern treatments. We evaluated HRQL in an international cohort of pediatric medulloblastoma patients. METHODS: Seventy-six patients were selected from 10 sites across North America, Europe, and Asia, who participated in the Medulloblastoma Advanced Genomics International Consortium (MAGIC). The Health Utilities Index (HUI) was administered to patients and/or parents at each site. Responses were used to determine overall HRQL and attributes (ie specific subdomains). The impact of various demographic and medical variables on HRQL was considered-including molecular subgroup. RESULTS: The majority of patients reported having moderate or severe overall burden of morbidity for both the HUI2 and HUI3 (HUI2 = 60%; HUI3 = 72.1%) when proxy-assessed. Self-care in the HUI2 was rated as higher (ie better outcome) for patients from Western versus Eastern sites, P = .02. Patients with nonmetastatic status had higher values (ie better outcomes) for the HUI3 hearing, HUI3 pain, and HUI2 pain, all P < .05. Patients treated with a gross total resection also had better outcomes for the HUI3 hearing (P = .04). However, those who underwent a gross total resection reported having worse outcomes on the HUI3 vision (P = .02). No differences in HRQL were evident as a function of subgroup. CONCLUSIONS: By examining an international sample of survivors, we characterized the worldwide impact of medulloblastoma. This is a critical first step in developing global standards for evaluating long-term outcomes.

Kinematic assessment of an elastic-core cervical disc prosthesis in one and two-level constructs.

INTRODUCTION: Anterior cervical discectomy and fusion has been associated with the development of adjacent segment degeneration (ASD), with clinical incidence of approximately 3% per year. Cervical total disc arthroplasty (TDA) has been proposed as an alternative to prevent ASD. HYPOTHESES: TDA in optimal placement using an elastic-core cervical disc (RHINE, K2M Inc., Leesburg, Virginia) will replicate natural kinematics and will improve with optimal vs anterior placement. METHODS: Seven C3-T1 cervical cadaver spines were tested intact first, then after one-level TDA at C5-C6 anterior placement, after TDA at C5-C6 optimal placement, after two-level TDA at C5-C6 and C6-C7 optimal placement, and finally after two-level TDA at C5-C6 lateral placement and C6-C7 optimal placement. The specimens were subjected to: Flexion-Extension moments (+1.5 Nm) with compressive preloads of 0 N and 150 N, lateral bending (LB) and axial rotation (AR) (+1.5 Nm) without preload. RESULTS: C5-C6 TDA in optimal placement resulted in a non-significant increase in flexion-extension ROM compared to intact under 0 N and 150 N preload (P > 0.05). Both LB and AR ROM decreased with arthroplasty (P < 0.01). Optimal placement of C6-C7 TDA resulted in an increase in flexion-extension ROM with preload compared to intact (P < 0.05) while LB and AR ROM decreased with arthroplasty (P < 0.01). CONCLUSION: This six degree of freedom elastic-core disc arthroplasty effectively restored flexion-extension motion to intact levels. In LB the TDA maintained 42% ROM at C5-C6 and 60% at C6-C7. In AR 57% of the ROM was maintained at C5-C6 and 70% at C6-C7. These findings are supported by literature which shows cervical TDA results in restoration of approximately 50% ROM in LB and AR, which is a multifactorial phenomenon encompassing TDA design parameters and anatomical constraints. Anterior placement of this viscoelastic TDA device shows motion restoration similar to optimal placement suggesting its design may be less sensitive to suboptimal placement.

Cost prediction in liver transplantation using pretransplant donor and recipient characteristics.

BACKGROUND: Liver transplantation is a costly procedure and its cost is likely driven by both donor and recipient factors. Recently, the recipient model for end-stage liver disease (MELD) score has been correlated with increased posttransplant cost; however, other factors have not been identified. We sought to identify if other donor and recipient factors are associated with increased cost. METHODS: One hundred sixty-six liver transplants performed at our center from January 2004 through February 2006 were included in the estimation sample, and the subsequent 75 transplants were used as a validation cohort. To determine whether donor factors influenced cost, two latent class linear regression models were created from the estimation sample: one considering only recipient variables (model A) and a second incorporating both donor and recipient factors (model B). The resultant models were then validated in the second group of patients and compared with the best single-segment linear regression models. RESULTS: Model A predictors include pretransplant intensive care unit (ICU) stay, age x body mass index, and calculated MELD. In model B, significant predictors are calculated MELD, age, age x pretransplant ICU stay, and donor age more than 40 as significant variables. In validation, only model A remained predictive of cost. CONCLUSIONS: Although marginal donor factors are recognized to influence clinical outcome, they did not factor significantly in cost modeling. In addition to MELD, the recipient factors of pretransplant ICU stay, age, and body mass index are pretransplant variables correlated mostly with posttransplant cost across broad populations.